CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY (CIGB)

Centre for Genetic Engineering and Biotechnology is a(( closed-loop research and technology centre. Through research and development, they have produced vaccines of international standards. Some vaccines made by CIGB include the Hepatitis B vaccine and an HPV vaccine comparable to CERVIRAX. Of great significance, is that CIGB developed a vaccine for the management of SARS-COVID-19, Abdala.

​

PRODUCT: Abdala
Abdala is a vaccine against SARS-COVID-19 that has completed its phase three trials and is currently on the list to be approved by the World Health Organization for emergency use. Abdala has a ninety-three (93%) efficacy against SARS COV-19 and has been used in children from age 5 years and upwards. This is significant as most other vaccines are still experimenting and evaluating accurate doses for children btw ages 5 and 12 years Abdala is proven to have eight-month protection after administration in three doses fourteen days apart. Abdala has a one hundred per cent (100%) efficacy in preventing severe disease and a one hundred per cent (100%) efficacy in preventing death in immunized patients. Abdala is stable at 2-8 degrees Celsius with no need to freeze, making its cold chain logistics easy to manage.

​

There have been very few side effects, with irritation at the injection site and mild drowsiness for 24 hours being the most common.